PharmaEssentia Appoints Fred Paster as Head of Commercial
June 20 2024 - 1:00PM
Business Wire
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia
Corporation (TWSE: 6446), a global biopharmaceutical innovator
based in Taiwan leveraging deep expertise and proven scientific
principles to deliver new biologics in hematology and oncology,
today announced the appointment of Fred Paster as Head of
Commercial.
Fred is a seasoned healthcare industry business leader who has
overseen research and business development pipelines across
oncology, specialty and rare diseases to commercial success, with
experience across the United States, Europe, Latin America and
Asia. As the new Head of Commercial at PharmaEssentia, Fred will be
responsible for the strategic growth of PharmaEssentia USA’s
capabilities and collaborations to enable transformative healthcare
solutions for patients with challenging diseases in the areas of
hematology, oncology and immunology. In his role, Fred will lead
the commercial teams, including sales, marketing and analytics.
"Fred has extensive experience at premier pharmaceutical
organizations growing pipelines and overseeing products across
their lifecycles, and we are thrilled to welcome him to
PharmaEssentia to help drive another commercial growth and
success,” said Dr. Ko-Chung Lin, PharmaEssentia Founder and Chief
Executive Officer. “This is an exciting time in our Company’s
growth, as we advance our commitment to provide new therapeutic
solutions for patients with myeloproliferative neoplasms and other
hematological diseases that have limited therapeutic options.”
Before coming to PharmaEssentia, Fred has a proven track record
as a leader in the healthcare industry with experience across the
United States, Europe, Latin America, and Asia, including serving
in leadership posts for Alexion Pharmaceuticals, Takeda Oncology
and Takeda Pharma International. Fred also has held multiple
commercial and marketing positions with Millennium Pharmaceuticals,
The Medicines Company and Boston Consulting Group. Fred received
his M.S. and B.S. at Massachusetts Institute of Technology and
M.B.A. at Harvard Business School. He is also a Chartered Financial
Analyst (CFA) charterholder.
About PharmaEssentia
PharmaEssentia (TWSE: 6446), headquartered in Taipei, Taiwan, is
a global and rapidly growing biopharmaceutical innovator.
Leveraging deep expertise and proven scientific principles,
PharmaEssentia aims to deliver effective new biologics for
challenging diseases in the areas of hematology, oncology, and
immunology with one approved product and a diversifying pipeline.
Founded in 2003 by a team of Taiwanese-American executives and
renowned scientists from U.S. biotechnology and pharmaceutical
companies, today PharmaEssentia is expanding its global presence
with operations in the U.S., Japan, China, and Korea, along with a
world-class biologics production facility in Taichung, Taiwan.
For more information about PharmaEssentia USA, visit the
website, LinkedIn or Twitter.
Forward Looking Statement
This press release may contain forward looking statements,
including statements regarding the clinical benefits to be derived
from ropeginterferon alfa-2b, the commercial opportunity and
competitive positioning, new indications or labeling for
ropeginterferon alfa-2b, and business prospects for ropeginterferon
alfa-2b. For those statements, we claim the protection of the safe
harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995 and similar legislation
and regulations under Taiwanese law. These forward-looking
statements are based on management expectations and assumptions as
of the date of this press release, and actual results may differ
materially from those in these forward looking statements as a
result of various factors. These factors include whether BESREMi is
successfully commercialized and adopted by physicians and patients,
the extent to which reimbursement is available for BESREMi, and the
ability to receive FDA and other regulatory approvals for
additional indications for BESREMi. We do not undertake to update
any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof.
© 2024 PharmaEssentia Corporation. All rights reserved.
PharmaEssentia, the PharmaEssentia logo, and BESREMi are
trademarks or registered trademarks of PharmaEssentia
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240620799506/en/
Media: Muriel Huang, muriel_huang@pharmaessentia.com